Screening potential anaphylactoid components in vinpocetine injection using a high expression Mas‐related G‐protein‐coupled receptor X2 cell membrane chromatography.

Vinpocetine injection is often used in clinical treatment of acute cardiovascular and cerebrovascular diseases. However, it was reported that vinpocetine injection caused allergic reactions in clinical use; therefore, its safety needs urgent attention. Until now, research on its sensitization is rarely reported. Here, the components contained in three vinpocetine injections were examined. It was found that besides vinpocetine, the synthetic raw material vincamine, the excipients benzyl alcohol and ethyl p‐toluenesulfonate, and the impurities A, B, C, and D, which are excipients specified in the European Pharmacopoeia, were also present in them. Then the Mas‐related G‐protein‐coupled receptor X2 (MRGPRX2)‐HEK293 cell membrane chromatography was used to investigate the affinity of them with MRGPRX2 and found that vinpocetine, vincamine, and impurities A, B, C, and D bind to MRGPRX2. Afterwards, these compounds were further used to investigate the local sensitization ability in vivo. The results showed that vinpocetine, vincamine, and impurity C could induce swelling of the paw and decrease body temperature in mice, but only impurity C could cause local skin mast cell degranulation and serum histamine release increase. In vitro, the results also indicated that impurity C could increase intracellular [Ca2+] in MRGPRX2‐HEK293 cells, whereas vinpocetine and vincamine did not. Therefore, the impurity C was the potential anaphylactoid component in vinpocetine injection, which may be one of the reasons for the occurrence of allergic reactions in the clinical use of vinpocetine injection. This work provides evidence on the sensitization of impurity C and also contributes to promoting the clinical safety of vinpocetine injection. Vinpocetine injection is used in clinical treatment of acute cardiovascular and was reported that caused allergic reactions in use without any research. Here, the components contained in three vinpocetine injections were examined. In this study, we demonstrate that impurity C in vinpocetine injection can activate MRGPRX2, a novel allergy‐like‐related receptor with potential sensitizing effects, and induce allergic symptom in vivo. The hazard of impurity C requires attention in clinical use of vinpocetine injection. [ABSTRACT FROM AUTHOR]